A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer

Chemotherapy

Volumn 58, Issue 1, 2012, Pages 78-83

  Mori, Kiyoshi ^a   Kamiyama, Yukari ^a   Kasai, Hisashi ^a   Kodama, Tetsuro ^a  

^a TOCHIGI CANCER CENTER   (Japan)

Author keywords

Carboplatin; First line chemotherapy; Gemcitabine; Lung cancer; Non small cell lung cancer; Weekly chemotherapy

Indexed keywords

CARBOPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84857495631     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000335601     Document Type: Article

References (30)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899-909.
2. Fukuoka M, Niitani H, Suzuki A, et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated nonsmall-cell lung cancer. J Clin Oncol 1992; 10: 16-20.
3. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced nonsmall cell lung cancer: A phase II study. J Clin Oncol 1994; 12: 1821-1826.
4. Chang AY, Rubins J, Asbury R, Boros L, Hui LF: Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol 2001; 28(4 suppl 14):10-13.
5. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC: Efficacy of navelbine (NVB) in non-small cell lung cancer (NSCLC). Semin Oncol 1989; 16(suppl 4):26-29.
6. Kunitoh H, Watanabe K, Onoshi T, et al: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: A Japanese cooperative study. J Clin Oncol 1996; 14: 1649-1655.
7. Bunn PA Jr., Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998; 5: 1087-1100.
8. Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T: A phase II study of docetaxel and infusional cisplatin in advanced non-smallcell lung cancer. Chemotherapy 2005; 51: 120-125.
9. Le Chevalier T, Scagliotti G, Natale R, et al: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced nonsmall-cell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 2005; 47: 69-80.
10. Kanzawa F, Saijo N: In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 1997; 24(suppl 7):8-16.
11. Peters GJ, Berbman AM, Ruiz van Haperen VWT, et al: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22(suppl 11):72-79.
12. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
13. Mori K, Kamiyama Y, Kondoh T, Kodama T: Phase II study of combination of gemcitabine and carboplatin in advanced non-small cell lung cancer (an interim report). Jpn J Cancer Chem 2008; 35: 931-935.
14. Zatloukal P, Petruzelka L, Zemanova M, et al: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 2003; 41: 321-331.
15. Rudd RM, Gower NH, Spiro SG, et al: Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: A phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005; 23: 142-153.
16. Sederholm C, Hillerdal G, Lamberg K, et al: Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23: 8380-8388.
17. Yamamoto N, Nakagawa K, Uejima H, et al: Randomized phase II study of carboplatin/ gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer. West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer 2006; 107: 599-605.
18. Masters GA, Argiris AE, Hahn EA, et al: A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced nonsmall-cell lung cancer. J Thorac Oncol 2006; 1: 19-24.
19. Kosmidis PA, Kalofonos HP, Christodoulou C, et al: Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 2008; 19: 115-122.
20. Schuette W, Blankenburg T, Schneider CP, et al: Randomized, multicenter, open-label phase II study of gemcitabine plus singledose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006; 2: 135-139.
21. Helbekkmo N, Sundstrøm SH, Aasebø U, et al: Norwegian Lung Cancer Study Group. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007; 97: 283-289.
22. Surmont V, Aerts JG, van Klaveren RJ, et al: A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced nonsmall cell lung cancer. Oncology 2010; 78: 267-270.
23. Akerley W, Safran H, Zaner K, et al: Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer 2006; 107: 1050-1054.
24. De Pas T, Putzu C, Curigliano G, et al: A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. Lung Cancer 2006; 54: 359-364.
25. Belani CP, Dakhil S, Waterhouse DM, et al: Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small cell lung cancer. Ann Oncol 2007; 18: 110-115.
26. Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T: A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2009; 64: 73-78.
27. Nakanishi Y, Takayama K, Wataya H, et al: Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors. Chemotherapy 2002; 48: 205-210.
28. Chung FT, Lee KY, Fang YF, et al: Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced nonsmall-cell lung cancer. Chemotherapy 2011; 57: 147-155.
29. Komuta K, Osaki T, Mori M, et al: A phase II study directed by a clinical pathway for carboplatin and weekly paclitaxel in previously untreated patients with unresectable nonsmall cell lung cancer. Chemotherapy 2010; 56: 39-45.
30. Simon R: Optimal two-stage designs for phase II clinical trial. Control Clin Trial 1989; 10: 1-10.